Present invention relates to methods for prediction of the therapeutic success of breast cancer therapy

A method of determining the prognosis for a patient afflicted with gynecologic cancer and receiving chemotherapy, said method comprising the steps of:

• a) obtaining a biological sample from said patient;
• b) combining the expression level data of at least two genes selected from the group comprising ALCAM, Osteo-pontin, Her-2/neu, EGFR, uPA/PAI-1 and/or ESRI in said sample;
• c) comparing the pattern of expression level(s) determined in (b) with one or several reference pattern(s) of expression levels;
• and
• d) determining the prognosis in said patient from the outcome of the comparison in step (c).

A method for correlating the clinical outcome of a patient suffering from or at risk of developing gynecologic cancer with the presence or non-presence of a defect in expression of at least one gene selected from the group comprising ALCAM, Osteopontin, Her-2/neu, EGFR, uPA/PAI-1 and/or ESRI, said method comprising the steps of:

• a) obtaining a (fixed) biological sample from said patient;
• b) determining the expression level of at least one of the said marker genes in said patient according to any of the above methods;
• and
• c) correlating the pattern of expression level(s) determined in (b) with said patient's data, said data being selected from the group consisting of etiopathology data, clinical symptoms, anamnesis data and/or data concerning the therapeutic regimen.